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Endocrine systems have long been suggested to be one of the important factors in neu-
ropsychiatric disorders, while the underlying mechanisms have not been well understood.
Traditionally, neuropsychiatric disorders have been mainly considered the consequence
of abnormal conditions in neural circuitry. Beyond the neuronal doctrine, microglia, one
of the glial cells with inflammatory/immunological functions in the central nervous sys-
tem (CNS), have recently been suggested to play important roles in neuropsychiatric
disorders. However, the crosstalk between neuroendocrine factors, neuropsychiatric dis-
orders, and microglia has been unsolved. Therefore, we herein introduce and discuss a
missing and possible link between these three factors; especially highlighting the fol-
lowing hormones; (1) Hypothalamic-Pituitary-Adrenal (HPA) axis-related hormones such
as corticotropin-releasing hormone (CRH) and glucocorticoids, (2) sex-related hormones
such as estrogen and progesterone, and (3) oxytocin. A growing body of evidence has
suggested that these hormones have a direct effect on microglia. We hypothesize that
hormone-induced microglial activation and the following microglia-derived mediators may
lead to maladaptive neuronal networks including synaptic dysfunctions, causing neuropsy-
chiatric disorders. Future investigations to clarify the correlation between neuroendocrine
factors and microglia may contribute to a novel understanding of the pathophysiology of
neuropsychiatric disorders.
Keywords: microglia, endocrinology, corticotropin-releasing hormone, glucocorticoids, sex hormones, estradiol,
oxytocin
INTRODUCTION
ENDOCRINE FACTORS AND NEUROPSYCHIATRIC DISORDERS
Endocrine systems play an important role in bridging the body
and the brain via various hormones, and maintaining homeosta-
sis in physical conditions, while hormone imbalances are known
to induce various physical disorders (Selye, 1950; Chrousos and
Gold, 1992). Endocrine organs, such as the adrenal gland and
the gonads, communicate with the central nervous system (CNS)
via neuroendocrine factors and contribute to a series of mental
functions. The network between the hypothalamus, pituitary, and
adrenal gland, called the Hypothalamic-Pituitary-Adrenal (HPA)
axis, is one of the crucial pathways in stress response (Selye, 1950;
Chrousos and Gold, 1992).
Abbreviations: ACTH, adrenocorticotropic hormone; ADIOL, 5-androsten-
3b,17b-diol; ASD, autism spectrum disorders; AVP, vasopressin; cADPR, cyclic-ADP
ribose; CRH, corticotropin-releasing hormone; CRH-R1, CRH receptor I; CRH-R2,
CRH receptor II; CtBP, C-terminal binding protein; ER, estrogen receptor; GABA,
gamma-aminobutyric acid; HPA axis, hypothalamic-pituitary-adrenal axis; HPG,
hypothalamic-pituitary-gonadal; IFN-γ, interferon gamma; IL, interleukin; LPS,
lipopolysaccharide; MeCP2, X -linked methyl-CpG-binding protein 2; MS, mul-
tiple sclerosis; NO, nitric oxide; O&NS, oxidative and nitrosative stress; PMDD,
premenstrual dysphoric disorder; PTSD, post-traumatic stress disorder; PVN, par-
aventricular nucleus; ROI, reactive oxygen intermediates; ROS, reactive oxygen
species; TNF-α, tumor necrosis factor-α.
The HPA axis is related to a variety of psychiatric conditions,
such as the depressive symptoms associate with Cushing syndrome
and steroid-induced depression (Lynn, 1995; Terao et al., 1997),
suggesting that the dysregulation of the HPA axis is possibly
involved with the pathophysiology of depression (Roy et al., 1988;
Lesch et al., 1990). On the other hand, reproductive functions
especially during pregnancy, birth, and the postnatal period are
exerted exclusively by the gonads through sex-related hormones.
Sex hormones establish the estrous cycle, and affect mental activi-
ties. The disturbance of estrous cycle functions is closely involved
with various symptoms of mood and emotion, frequently develop-
ing into mood disorders such as premenstrual dysphoric disorder
(PMDD) (Steiner et al., 1995; Epperson et al., 2002) and depressive
disorders during perinatal (Bloch et al., 2000) and perimenopausal
periods (Freeman et al., 2004a). Interestingly, oxytocin, the neu-
roendocrine hormone mainly associated with the postnatal period,
has recently been highlighted for its stress-suppression effects and
prosocial functions. Oxytocin has been shown to be involved with
anxiety and depressive mood in patients with depression (Scant-
amburlo et al., 2007). Oxytocin exerts anxiolytic effects through
the reduction of stress-induced corticosterone release on rodents
(Windle et al., 1997) and also on healthy humans exposed to
stress (Heinrichs et al., 2003). Additionally, oxytocin has been sug-
gested to be an important factor in mental development and its
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abnormality may be related to autism (Tetreault et al., 2012). The
above-mentioned reports all suggest that the HPA axis-related
hormones, sex hormones, and oxytocin have a possible link to
psychiatric disorders, while the underlying biological mechanisms
have not been well understood.
NOVEL UNDERSTANDINGS OF NEUROPSYCHIATRIC DISORDERS
Traditionally, abnormalities of neurons and neuronal networks
including synaptic abnormalities and disturbance of neurotrans-
mitters have dominantly been believed to be the main causes of
psychiatric disorders. Beyond these classic understandings, novel
theories have been presented that psychiatric disorders are sys-
temic disorders widely driven by peripheral inflammatory and
oxidative and nitrosative stress (O&NS) processes, and in addi-
tion that neuropsychiatric disorders are controlled by inflam-
matory, immune, O&NS, tryptophan catabolite, neuroinflamma-
tory and neuroprogressive pathways in the CNS (Maes, 2011;
Maes and Rief, 2012). Moreover, systemic inflammatory and
O&NS processes heavily modulate hormonal levels, and recipro-
cal relationships between peripheral inflammation and hormonal
levels are suggested to be involved in the pathophysiology of
these disorders (Maes, 2011; Maes and Rief, 2012). In the brain,
tryptophan catabolites such as kynurenine, kynurenic acid, 3-
hydroxykynurenine, and quinolinic acid are synthesized in glia
cells, and recent reports have shown that the blood kynure-
nine/tryptophan ratio is elevated in patients with depression and
correlated with anxiety and cognitive disturbances (Schwarcz et al.,
2012). Steiner et al. (2011) have shown pivotal findings that quino-
linic acid positive microglia increase in the subgenual anterior
cingulate cortex and anterior midcingulate cortex of patients with
major depressive disorder (MDD) but not bipolar disorder. A
relationship between the kynurenine pathway and depression is
supposed to be induced by the activation of indoleamine 2,3-
dioxygenase (IDO), an intracellular enzyme that catalyzes tryp-
tophan degradation into kynurenine. However, how tryptophan
catabolites correlate with depression pathology remains to be
elucidated.
NEUROPSYCHIATRIC DISORDERS AND MICROGLIA
Macrophages in peripheral organs play important roles in the
process of peripheral inflammation (Kiefer et al., 2001; Mosser
and Edwards, 2008). Similarly, microglia, one of the immune
cells in the brain, play crucial roles in neuroimmunology includ-
ing neuroinflammatory and neuroprogressive pathways. Microglia
were initially discovered by Del Rio-Hortega (1919). Tradi-
tionally, neuroscientists regarded microglial function simply to
provide physical support and maintenance for neurons. Thus,
microglia had been long ignored (Miller, 2005). However stud-
ies during the last 20 years have elucidated various biological
functions of microglia that act as “brain macrophage”; crucial
immunological/inflammatory players moving around, monitor-
ing micro-environmental changes, and once activated, releas-
ing pro-inflammatory cytokines such as tumor necrosis factor
(TNF)-α and free radicals including nitric oxide (NO), and
finally inducing neuropathologies such as phagocytosis, apoptosis
of neuronal cells, suppressing neurogenesis, and oligodendro-
cyte dysfunction (Block et al., 2007; Hanisch and Kettenmann,
2007). Thus, microglia have proved to play important roles in
neurodegenerative diseases and neuropathic pain (Inoue and
Tsuda, 2009; Graeber, 2010; Graeber and Streit, 2010; Kettenmann
et al., 2011; Ransohoff and Stevens, 2011).
Recent positron emission tomography (PET) imaging of
peripheral benzodiazepine receptors and postmortem studies have
suggested microglial activation in the brain of patients with neu-
ropsychiatric disorders such as schizophrenia, depression, and
autism (Steiner et al., 2006, 2008; van Berckel et al., 2008; Door-
duin et al., 2009; Morgan et al., 2010; Takano et al., 2010; Tetreault
et al., 2012; Suzuki et al., 2013). Interaction between microglial
activation and psychopathology has not been well clarified, while
a PET study has resulted in an interesting outcome; Takano
et al. (2010) reported that chronic schizophrenia patients showed
a positive correlation between cortical [11C]DAA1106 binding
(one of the peripheral benzodiazepine receptors ligand) and pos-
itive symptom scores which were assessed using the Positive and
Negative Syndrome Scale. Although the correlations need to be
interpreted very cautiously, involvement of microglial activation
in the pathophysiology of positive symptoms of schizophrenia
might be suggested. Animal models of neuropsychiatric disorders
such as schizophrenia and autism have proposed the underlying
microglial pathologies (Juckel et al., 2011; Derecki et al., 2012;
Liaury et al., 2012). In addition, various psychotropic drugs,
which had classically been regarded to modulate solely neurons
and synaptic networks, have recently been revealed to have direct
anti-inflammatory properties on activated microglia in a series of
in vitro studies (Hashioka et al., 2007; Kato et al., 2007, 2008, 2011b;
Horikawa et al., 2010). Therefore, microglia may play crucial
roles in the pathophysiology and treatment of neuropsychiatric
disorders (Monji et al., 2009, 2013; Kato et al., 2011a, 2013).
In addition, minocycline, a tetracycline antibiotic, has recently
been known to improve symptoms of psychiatric disorders such
as schizophrenia (Miyaoka et al., 2007; Miyaoka, 2008; Levkovitz
et al., 2010). Minocycline has a variety of functions in the CNS
such as interacting with brain glutamate and dopamine neuro-
transmission (Kim and Suh, 2009) and having direct effects on
neuronal cells (Hashimoto and Ishima, 2010). Rodent studies have
revealed that minocycline inhibits microglial activation (Yrjan-
heikki et al., 1998), and in actuality it is one of the most frequently
used drugs for inhibiting microglial activation (Yrjanheikki et al.,
1999; Du et al., 2001; Kim and Suh, 2009). Several rodent stud-
ies have shown that stress increases microglial activation (Frank
et al., 2007; Sugama et al., 2009; Tynan et al., 2010), and causes
anxiety-like behaviors, which in turn can be decreased by minocy-
cline treatment (Neigh et al., 2009). These in vivo studies have
suggested that minocycline may be effective for the treatment of
psychiatric disorders. An open-label study has shown that selective
serotonin reuptake inhibitor (SSRI) and minocycline attenuate
depressive and psychotic symptoms in patients with psychotic
depression (Miyaoka et al., 2012). In addition, minocycline has
been reported to be effective for the treatment of various symp-
toms in patients with Fragile X syndrome (FXS) such as social
communication, anxiety, irritability, stereotypy, hyperactivity, and
inappropriate speech (Paribello et al., 2010; Utari et al., 2010).
Previous microglia research has mainly highlighted the neu-
ropathological aspects of microglia, while recent animal studies
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have shown the normal functions of microglia (Graeber, 2010;
Ransohoff and Stevens, 2011; Tremblay et al., 2011; Graeber and
Christie, 2012; Schafer et al., 2012). Rodent microglia have been
revealed to monitor synaptic reactions by having continuous direct
contact with synapses not only in pathological brain but also in
normal brain (Wake et al., 2009), and have proved to play essential
roles in brain development such as in synaptic pruning (Paolicelli
et al., 2011; Schafer et al., 2012). Therefore, even in normal condi-
tions, microglia have been revealed to have some crucial roles in
the homeostasis of synaptic conditions and in brain development.
Moreover, we have recently reported that human social activities
such as decision-making are modulated by minocycline not only in
psychiatric patients but also in healthy persons (Kato et al., 2012;
Watabe et al., 2012). Our human neuroeconomics studies have
implied the possibility that brain development including neuron-
microglia network establishment may formulate personality, and
personality-oriented behaviors may be modulated by microglia
(Kato et al., 2012). Thus, we suppose that microglia could be
one of the crucial players in human mental development dur-
ing early stages, and also in various social/mental activities after
developmental stages including under healthy and pathological
conditions beyond the neuron-synapse doctrine. A recent PET
study has shown that minocycline inhibits microglial activation in
humans (Dodel et al., 2010), thus we can prospect that minocycline
may actively modulate human microglial activity.
Based on the above-mentioned reports, we hypothesize that
microglia may be one of the bridging players between these
highlighted neuroendocrine factors, normal/pathological mental
conditions, and psychiatric disorders, while the underlying biolog-
ical mechanisms have yet to be well considered. In addition, it is
unknown whether microglia release neuroendocrine factors, while
recent studies have suggested that these hormones affect microglia.
Therefore, in this article, we would like to introduce and discuss
the missing and possible link between the above-mentioned neu-
roendocrine factors, neuropsychiatric disorders, and microglia.
HYPOTHALAMIC-PITUITARY-ADRENAL AXIS-RELATED
HORMONES
The HPA axis is the major stress response system which connects
peripheral organs and the brain (Selye, 1950; Chrousos and Gold,
1992). In response to stress, corticotropin-releasing hormone
(CRH) is secreted by the paraventricular nucleus (PVN) of the
hypothalamus, and released into the pituitary gland, where CRH
induces the release of adrenocorticotropic hormone (ACTH).
Thereafter, ACTH activates the adrenocortical secretion of glu-
cocorticoids. Finally, glucocorticoids suppress the release of CRH
and ACTH as a negative feedback.
HPA AXIS AND PSYCHIATRIC DISORDERS
A variety of psychiatric symptoms due to primary physical ill-
ness are related to the HPA axis, such as the depressive symptoms
associate with Cussing syndrome and steroid-induced depression
(Lynn, 1995; Terao et al., 1997). The significant higher concen-
tration of CRH and ACTH, induced by the initial injection of
interferon (IFN)-α, has been found in patients with the subse-
quent development of depression during IFN-α treatment than in
those without depression (Capuron et al., 2003).
The HPA axis has also been suggested to have a strong linkage to
psychiatric disorders such as mood disorders and post-traumatic
stress disorder (PTSD) (Baker et al., 1999; Holsboer, 2000; Kunugi
et al., 2006). Baker et al. (1999) reported that CRH levels in
cerebrospinal fluid were significantly greater in PTSD patients
than in normal subjects. The dysregulation of the HPA axis is
suggested to be involved with the pathophysiology of depres-
sion (Roy et al., 1988; Lesch et al., 1990). Previous studies have
revealed the blunted responses to stressful events in patients with
MDD, especially patients with a familial history of mood disor-
ders and with men compared to women (Peeters et al., 2003).
Investigations with depressed patients have shown that the num-
ber of CRH neurons increases in the PVN of the hypothalamus
of patients with depression (Raadsheer et al., 1994), and pitu-
itary volume decreases in patients with bipolar disorder (Sassi
et al., 2001). ACTH has been reported to induce depressive-like
behaviors through NMDA receptors in rats (Tokita et al., 2012).
Glucocorticoids are also thought to be involved in various psychi-
atric disorders and related emotional disturbances (Brown, 2009;
Laan et al., 2009; Ros-Bernal et al., 2011). Recently, Niwa et al. have
reported the essential role of glucocorticoids in the association
between adolescent stress and gene-environmental interactions
using a mouse model with dominant-negative DISC1 (Disrupted
Schizophrenia 1) under isolation during adolescence, and sug-
gested this mouse as a candidate model for psychotic depression.
They have revealed that via the epigenetic functions of glucocor-
ticoids, adolescent stress induces projection, originating from the
ventral tegmental area, specific methylation of tyrosine hydroxy-
lase, and subsequently causes some neurochemical and behavioral
deficits in this model mouse (Niwa et al., 2013). These reports
have suggested that the HPA axis is one of the key components
in understanding the deeper mechanisms of mood disorders and
other psychiatric disorders.
CORTICOTROPIN-RELEASING HORMONE AND MICROGLIA
Corticotropin-releasing hormone, otherwise known as corticotro-
pin-releasing factor (CRF), is a 41-amino acid peptide hormone,
originally derived from a 191-amino acid preprohormone (Vale
et al., 1981). The main site of CRH production is neurons in
the parvocellular division of the hypothalamic PVN. CRH is also
distributed in the limbic system such as other areas of the hypo-
thalamus and amygdala, the locus ceruleus of the brain stem, A1,
A5 catecholaminergic cell groups, and cerebral cortices (Chappell
et al., 1986; Dunn et al., 2004; Chandrasekar et al., 2007). CRH
mainly binds to CRH receptor I (CRH-R1). Urocortin, which also
binds to CRH-R1, was discovered in rat midbrain (Vaughan et al.,
1995), and is now characterized in three subtypes as urocortin-
I/II/III (Lewis et al., 2001; Pelleymounter et al., 2004). Urocortins
have high affinity to another CRH receptor; CRH receptor II
(CRH-R2). Urocortin-II and urocortin-III specifically bind to
CRH-R2. Urocortins are known to modulate various aspects; for
example, appetite and anxiety in the brain, and the cardiovascular
system in peripheral organs (Oki and Sasano, 2004).
Rat microglia have functional CRH-R1, and CRH has shown
to bind to CRH-R1 (Wang et al., 2002), which results in microglial
proliferation and TNF-α release via mitogen-activated protein
kinase (MAPK) signaling pathways (Wang et al., 2003). On the
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other hand, Ock et al. reported that CRH induced an apopto-
sis of mice microglia, and did not influence NO production or
expression of pro-inflammatory genes, indicating that CRH did
not affect the inflammatory activation of microglia. The CRH-
induced microglial apoptosis has shown to involve a mitochondrial
pathway and reactive oxygen species (ROS), based on the mito-
chondrial membrane potential change, caspase 9 activation, and
sensitivity to antioxidants (Ock et al., 2006). These reports have
suggested that CRH induces a part of pro-inflammatory reactions
and/or oxidative stress, while further investigations are needed for
a more detailed understanding.
Interleukin (IL)-18 has been suggested to be one of the cru-
cial cytokines modulating stress responses (Tringali et al., 2005).
Microglia is the major source of IL-18 in the brain (Prinz and
Hanisch, 1999). Recent reports have suggested that IL-18 may
play a significant role in psychiatric disorders such as depres-
sion and PTSD (Shirts et al., 2008; Mehta et al., 2011; Prossin
et al., 2011; Xiu et al., 2012). Yang et al. (2005) reported that CRH
enhanced IL-18 mRNA expression and significantly induced the
secretion of functional IL-18 protein in mouse BV2 microglial
cells. IL-18 knockout mice showed less microglial activation after
acute stress, which resulted in less damage of dopamine neurons
(Sugama et al., 2004, 2007). On the other hand, CRH increased the
generation of intracellular reactive oxygen intermediates (ROI),
and CRH-induced IL-18 production was blocked by an antioxi-
dant, N -acetyl-l-cysteine (NAC) in mouse microglia (Yang et al.,
2005). This report suggests that stress response is involved in reg-
ulating CRH-induced IL-18 production via ROI modification in
microglia.
Meanwhile, microglia in rat/mice also have functional CRH-
R2 receptors (Wang et al., 2007). Urocortin suppressed the release
of TNF-α from lipopolysaccharide (LPS)-activated microglia via
CRH-R2, and attenuated the LPS-induced neuronal damage on
neuron-microglia mix culture (Wang et al., 2007). This report
indicates the possibility that urocortin has neuroprotective prop-
erties via anti-inflammatory effects on microglia, similar to other
immunological cells (Gonzalez-Rey et al., 2010). A recent study
using a triple urocortin knockout mouse model has suggested
that urocortins play an essential role in stress recovery (Neufeld-
Cohen et al., 2010). The latest study has revealed that CRH and
urocortin modulate spinal outgrowth and synaptic formation via
CRH receptors (Gounko et al., 2013). Direct interactions between
microglia and these functions of CRH and urocortins have not
been investigated (Neufeld-Cohen et al., 2010; Gounko et al.,
2013),while we suppose that microglia may play an important role.
GLUCOCORTICOIDS AND MICROGLIA
To our knowledge, a direct relationship between ACTH and
microglia has not been reported. On the other hand, glucocor-
ticoids, another key modulator of the HPA axis, are suggested
to induce microglial modulation in the CNS (Sorrells et al.,
2009). Previous studies have discussed the role of glucocorti-
coids as moderators of stress-related neuroinflammation (Dinkel
et al., 2003; Munhoz et al., 2010; Loram et al., 2011). Smith
et al. (1991) reported that adrenalectomy powerfully potentiates
CNS inflammatory responses. Regarding microglia, Tanaka et al.
(1997) have reported that cultured microglia isolated from the
forebrain of newborn rats express glucocorticoid receptor in the
plasma membrane. Sierra et al. (2008) have shown that corti-
costerone attenuated the production of TNF-α, IL-6, and NO
from LPS+ IFN-γ-activated murine microglia, which suggests
that the anti-inflammatory effect of glucocorticoids on microglia
is inverted to that of CRH. The stress-induced elevation of gluco-
corticoids has been well known (Munck et al., 1984), and it has
proven to activate microglia in rats (Sugama et al., 2007; Tynan
et al., 2010) and promote the proliferation of microglia via NMDA
receptor activation in mice (Nair and Bonneau, 2006). From the
temporal point of view it is important to categorize stress into
two types; acute and chronic stress (Frank et al., 2010). Stress and
administration of glucocorticoids prior to the injection of LPS,
a peripheral immune stimuli, exerts pro-inflammatory effects on
microglia in rats (de Pablos et al., 2006; Frank et al., 2010, 2012).
On the contrary, exposure to glucocorticoids after LPS stimula-
tion has anti-inflammatory properties in rats (Frank et al., 2010).
In macrophage, glucocorticoids have been reported to exert pro-
inflammatory effects through the increased NOD-like receptor
(NLR) P3 mRNA and protein, which is a critical component of the
inflammasome (Busillo et al., 2011). Deeper mechanisms of pro-
and/or anti-inflammatory effects of glucocorticoids on microglia
have not been well clarified, while a recent study has suggested
that corticosteroids limit microglial activation occurring during
acute stress when using adrenalectomy plus corticosterone admin-
istered rats (Sugama et al., 2013). Further investigations should be
conducted to dig up the deeper mechanism.
CLINICAL IMPLICATIONS
The HPA axis has long been suggested to have strong linkage to
psychiatric disorders, and the role of hormones such as CRH and
glucocorticoids have been considered within the understanding of
the HPA axis. Our highlighted evidence that CRH and glucocor-
ticoids directly affect microglia sheds new light on understanding
the unsolved roles of CRH and glucocorticoids in psychiatric dis-
orders and psychopathologies. CRH and glucocorticoids directly
and/or mutually modulate activities of microglia, and activated
microglia release pro-inflammatory mediators, which may result
in various psychiatric symptoms such as anxiety, fear, and depres-
sion beyond the classical understanding of the HPA axis (Figure 1).
So far, the underlying mechanism of the mutual effects of CRH and
glucocorticoids on microglia has not been well understood, while
such novel knowledge will provide a systematic understanding of
psychiatric disorders. Further basic, clinical and translational stud-
ies of CRH and glucocorticoids focusing on microglia should be
investigated.
SEX HORMONES
Sex hormone system, frequently conceptualized as the
hypothalamic-pituitary-gonadal (HPG) axis, is one major cate-
gory of hormones correlated with mental conditions. Sex hor-
mones such as estrogen, progesterone, and testosterone have cru-
cial roles in health. Estrogen is one of the important steroid
hormones and mainly classified into estrone, estradiol, and estriol.
Androstenedione and testosterone metabolized from cholesterols
in theca cells can be aromatized to estrone and estradiol in granu-
losa cells, respectively. Estradiol is also produced in various regions
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FIGURE 1 | CRH and glucocorticoids affect microglia beyond the HPA
axis.
such as the adrenal gland, the mammary gland, adipose tissues,
and the brain. From puberty to menopause, estrogens establish
and maintain the reproductive function during the estrous cycle.
In addition to these functions, estrogens have systemic functions
that include for example, developing the mammary gland, regu-
lating the immune system, protecting the cardiovascular system,
and maintaining bones. At the same time, the remarkable involve-
ment of estrogens in the brain have recently been highlighted, and
the mechanism underpinning these functions such as enhanc-
ing cognitive function has gradually been clarified (Walf et al.,
2011). Progesterone, one of the steroid hormones from the corpus
luteum, is involved in the female reproductive system, especially
developing the mammary gland and the initiation and mainte-
nance of pregnancy (Mani and Portillo, 2010). Androgens are
steroid hormones that are essential not only to the establishment
and maintenance of male reproductive functions but also to mus-
cular and bone anabolic functions (Yin et al., 2003). The most
primary androgen is testosterone secreted by Leydig cells in the
presence of luteinizing hormone (Mooradian et al., 1987). During
reproductive age, sex hormones levels alter along with life stages
of women. Estrogen and progesterone progressively increase dur-
ing pregnancy, and after the delivery, both hormones abruptly
decrease and a normal estrous cycle is restored. Also, both hor-
mones gradually begin to decrease from the climacteric period
toward menopause, but LH and FSH simultaneously increase dur-
ing this period. In this way, sex hormones in women demonstrate
cyclic alteration along with ovulation, and also the balance of sex
hormones changes at the time of pregnancy or menopause, caus-
ing some women to show various psychiatric symptoms which
occasionally develop into psychiatric disorders (Steiner et al.,
2003).
SEX HORMONES, MENTAL CONDITIONS, AND PSYCHIATRIC
DISORDERS
Women are more likely to show unipolar depression than men
(Nolen-Hoeksema, 1987), and severe stresses are more likely to
induce depression in women (Kendler et al., 1995). Sex hormones
alter with time and subsequently establish the estrous cycle, which
plays an important role in depression.
Neurosteroids such as pregnenolone, progesterone, and dehy-
droepiandrosterone (DHEA) have been suggested to have positive
links to neuropsychiatric disorders. For example, the CSF level
of pregnenolone is lower in patients with MDD than healthy con-
trols (George et al., 1994). The saliva and serum level alterations of
DHEA during depressive episodes have revealed divergent results
(Eser et al., 2006), but recently Kurita et al. (2013) have reported
elevated levels of serum DHEA in male and female patients with
MDD. Both pregnenolone and DHEA probably have therapeutic
effects for patients with MDD (Wolkowitz et al., 1999; Schmidt
et al., 2005; Osuji et al., 2010). Considering the binding abili-
ties of pregnenolone, DHEA/DHEA-sulfate (DHEA-S), proges-
terone, and testosterone to sigma-1 receptors, and of DHEA-S and
progesterone to GABAA receptors, these receptors may be a pos-
sible link between neurosteroids and neuropsychiatric disorders
(Hashimoto, 2013).
Altered mental conditions during premenstrual period
Sex hormones are widely known to influence mental conditions.
Many women with existing psychiatric disorders complain of
worse mental symptoms before menstruation and experience var-
ious physical and mental symptoms of premenstrual syndrome.
Some women with PMS show severe symptoms and are psychiatri-
cally diagnosed with PMDD under the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) (Steiner,
2000). From the latter luteal phase to the just beginning of men-
struation patients with PMDD show various mental symptoms
such as depressive mood, anxiety, irritability, and insomnia. The
levels of estrogen and progesterone drastically alter during the
same period, suggesting that the alteration of sex hormones levels
may be associated with the pathology of PMDD. Administering
progesterone increases the reactivity of the amygdala in women
with no symptoms during the follicular phase (van Wingen et al.,
2008) and causes various physical and mental symptoms in post-
menopausal women (Hammarback et al., 1985; Magos et al., 1986),
suggesting that progesterone induces various psychiatric symp-
toms in women. However, the direct association between the level
of progesterone and PMS/PMDD has not been confirmed (Rubi-
now et al., 1988; Schmidt et al., 1991). Patients with PMS/PMDD
may be vulnerable to the fluctuation of the levels of estrogen
and/or progesterone. Some reports using acoustic startle response
or prepulse inhibition have shown that the response to the fluctua-
tion of sex hormones differs between healthy women and patients
with PMDD (Kask et al., 2008). Animal studies have suggested that
the alterations of the level of estrogen/progesterone are positively
associated with aggression (Ho et al., 2001) and the depressive
trend (Schneider and Popik, 2007).
Altered mental conditions during postpartum period
Both estrogen and progesterone levels increase during pregnancy,
and abruptly decrease after delivery. A few days after childbirth,
many women show mild depressive mood, tearfulness, anxi-
ety, irritability, dysphoria, and insomnia; generally referred to as
“maternity blues” and considered to be a transient psychological
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response (Newport et al., 2002). Maternity blues is also a risk factor
for depression and anxiety disorder within 3 months after delivery
(Reck et al., 2009). Psychiatric disorders including depression are
well known to appear frequently during the perinatal period, and
estrogen and progesterone are suggested to be involved with the
development of postnatal depression (Bloch et al., 2000). Freeman
et al. (2002) have reported that 67% of women with bipolar dis-
order experience a postpartum mood episode, emphasizing the
problem of the relapse and recurrence of a mood episode. Post-
partum psychosis is a rare psychiatric disease characterized by
hallucinations, delusions, mood swing, etc (Brockington et al.,
1981). A lower blood concentration of estradiol is observed in
patients of postnatal psychosis compared to normal controls,
therefore the administration of estradiol could be effective to
patients who are resistant to neuroleptic medications (Ahokas
et al., 2000). Moreover transdermal estrogen replacement therapy
has been reported to be an effective treatment of severe postnatal
depression (Gregoire et al., 1996).
Depression during the menopausal transition
Sex hormonal changes and the estrous cycle become gradually
irregular during menopausal transition, consequently causing cli-
macteric syndromes including such physical symptoms as vaso-
motor symptoms (hot flashes and night sweat), and vaginal dry-
ness, and mental symptoms such as depression and irritability
(Anon, 2005). A controversial issue is that the risk for depres-
sion may be high during the periods of premenopausal, peri-
menopausal, and/or postmenopausal. Women with a history of
PMS have been reported to be susceptible to depression during
the perimenopausal period (Freeman et al., 2004b). Woods and
Mitchell (1996) have suggested the association between consistent
depressive symptoms during the perimenopausal period and a his-
tory of postpartum depressive symptoms. Morrison et al. (2004)
have reported that hormonal replacement therapy is effective for
women with postpartum and premenopausal depression, but not
for women with postmenopausal depression. The mechanism of
the pathogenesis of psychiatric disorders during menopausal tran-
sition remains controversial possibly because of the few studies
utilizing rigorous measurements such as The Structured Clinical
Interview for DSM-IV (SCID). By utilizing the SCID for women
without a current or past history of depression, Schmidt et al.
(2004) have revealed that the risk for onset of depression is 14
times as high as for a 31-year premenopausal period of time. In the
Study of Women’s Health Across the Nation (SWAN), Bromberger
et al. (2009) initially reported no association between the peri-
menopausal period and the risk for onset of depression diagnosed
by SCID, but afterward, they have reported that the risk of major
depression is greater for women during and immediately after the
menopausal transition than for women during the premenopausal
period (Bromberger et al., 2011). A higher blood concentration of
testosterone is found in untreated premenopausal women with
depression compared to normal controls (Baischer et al., 1995). A
lower blood concentration of estradiol during the follicular phase
and a shorter half-life of luteinizing hormone during both the
follicular and luteal phase are found in premenopausal women
with depression (Young et al., 2000). There is a significant nega-
tive correlation between the blood concentration of estradiol and
Hamilton depression scores in depressed premenopausal women
(Baischer et al., 1995). During transition to the menopausal period,
women suffering from depressive symptoms increase, and con-
trastively, these symptoms decrease after menopause (Freeman
et al., 2004a). Transdermal estrogen replacement therapy has
been known to be effective for patients with depressive symp-
toms during the perimenopausal period (Soares et al., 2001).
In this way, there are various arguments about perimenopausal
depression. However, it’s certain that sex hormones changes and
also consequent stresses occur during the perimenopausal period,
and this with addition of factors such as aging, the increase of
physical illness, the changing role of women in society and fam-
ily, and so on, the risk for depression during perimenopausal
period may increase. The association between the estrous cycle
and depression is probably bidirectional and interactive, making
it difficult to understand the mechanism of the pathogenesis of
perimenopausal. A history of major depression may be correlated
with early onset of menopause due to an early diminution of ovar-
ian function (Harlow et al., 2003). Studies in animal experiments
frequently adopt an ovariectomy model, but surgically induced
menopause after ovariectomy cannot be always identified with
natural menopause. These facts make it difficult to research the
mental condition during perimenopausal period.
Other psychiatric disorders associated with sex differences
Sex hormonal differences may also be related to some other psy-
chiatric disorders; for example, autism including adult Autism
Spectrum Disorders (ASD) is more common in men than women
(Brugha et al., 2011). Schizophrenia occurs with equal rates in
both sexes, but it has been widely known that schizophrenia in
women occurs in older ages and female patients with schizo-
phrenia have better prognoses than men with schizophrenia. The
plasma level of testosterone in male patients with bipolar disorder
has been reported to be positively correlated with the number of
manic episodes and the number of suicide attempts (Sher et al.,
2012). These reports suggest the importance role of sex hormones
in psychiatric disorders. So far, a great number of studies have
been conducted with the traditional view of sex hormones acting
mainly on neurons and neurotransmitters, but a few recent stud-
ies have highlighted the association between the sex hormones and
microglia.
SEX HORMONES AND MICROGLIA
The relationship between sex hormones and microglia has not
been well understood. However, some studies have recently
presented interesting facts about the relationship.
Estrogen
Several investigations suggest that some sex hormones have anti-
neuroinflammatory and neuroprotective activities via microglia.
In vitro studies using rat microglial cells have revealed that
estradiol inhibits phagocytosis, the production of ROS (Bruce-
Keller et al., 2000), and LPS-induced pro-inflammatory molecules
such as inducible nitric oxide synthase (iNOS), prostaglandin E2
(PGE2), and matrix metalloproteinase-9 (MMP-9) (Vegeto et al.,
2001). The expression of rat microglial neuroinflammatory genes
by the immunosuppressive functions of estradiol is mediated via
estrogen receptor alpha (ERα) and beta (ERβ) (Sarvari et al., 2011).
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It is important to investigate the response of microglia to var-
ious pro-inflammatory stimuli from the perspective of age and
sex differences. Morphology and numbers of microglia alter dur-
ing developmental stages. For instance, there are more microglia
derived from male postnatal rats during an early stage of devel-
opment than female, and the shapes of microglia derived from
female postnatal rats during later developmental stages tend to be
amoeboid type (Schwarz and Bilbo, 2012). The distinct microglial
expression of genes of cytokines, chemokines, and receptors are
attributed to age and sex differences (Schwarz and Bilbo, 2012).
Similarly, expression of P2 purinergic receptors varies with age and
sex in murine microglia (Crain et al., 2009). Estradiol has proved
to play distinct roles depending on the situation. For instance, in
female neonatal rats, microglia express more IL-1β with estradiol
in vitro, that is to say, estradiol exerts a pro-inflammatory effect
on female microglia, and on the contrary, estradiol has an anti-
inflammatory effect on male microglia. Moreover, in adult rats,
estradiol has pro-inflammatory effects without sex differences ex
vivo (Loram et al., 2012). Chronic administration of estradiol
in vivo results in the activation of microglia derived from the
female hippocampus inducing IL-1β expression stimulated with
LPS (Loram et al., 2012). These reports have suggested that estra-
diol plays different roles in modulating microglia depending on
age and sex.
A remarkable function of estrogen receptor on microglia
has recently been elucidated. 5-androsten-3b,17b-diol (ADIOL),
converted from dehydroepiandrosterone by 17b-hydroxysteroid
dehydrogenase type 14 (HSD17B14), has been proved to sup-
press inflammatory responses of microglia and astrocytes by
the recruitment of C-terminal binding protein (CtBP) through
an ERβ dependent mechanism (ADIOL/ERβ/CtBP transrepres-
sion pathway in microglia). Moreover, through this pathway, the
administration of ADIOL has prevented and inhibited experimen-
tal autoimmune encephalomyelitis (EAE), an animal model of
multiple sclerosis (MS) (Saijo et al., 2011).
Progesterone/testosterone
Progesterone is widely known to play an important role in inflam-
mation in the peripheral organs and the CNS (Stein, 2001; Brinton
et al., 2008; Challis et al., 2009). Progesterone and testosterone also
regulate microglial functions. Progesterone antagonizes estradiol
in synaptic remodeling,which is mediated by a progesterone recep-
tor on microglia in rats (Wong et al., 2009). Brain injury increases
the expression of aromatase that metabolizes testosterone to estra-
diol, and the administration of testosterone reduces the number
of astrocytes and microglia in the lesion (Barreto et al., 2007).
Prolactin
Prolactin is a sex-related hormone. Prolactin is mainly synthe-
sized by and secreted from the anterior lobe of pituitary gland.
The secretion of prolactin is mediated by prolactin inhibiting fac-
tors, predominantly dopamine (Ben-Jonathan and Hnasko, 2001),
and prolactin releasing factors such as TRH and oxytocin (Egli
et al., 2010). Other factors stimulating the secretion of prolactin
include suckling and various stresses (Otte et al., 2002; Lennarts-
son and Jonsdottir, 2011). Prolactin has multiple functions such as
lactation, maintenance of gestation, mediating maternal behavior
(Freeman et al., 2000), and has been suggested to have anxiolytic
and anti-stress effects on the evidence of an experiment with rats
(Torner et al., 2001).
Möderscheim et al. have just reported the first possible cor-
relation between prolactin and microglia. They have shown that
unilateral hypoxic ischemic injury in rats made astrocytes and
reactive microglia strongly prolactin immunoreactive, and pro-
lactin immunoreactivity was increased in the affected cortex pro-
lactin. On the other hand, prolactin and prolactin receptors were
decreased on penumbral neurons. In this report, prolactin has
been proved to be proliferative for astrocytes in vitro, but it has
been uncertain whether prolactin has any effect on microglia
(Möderscheim et al., 2007).
CLINICAL IMPLICATIONS
As stated above, we are just in the early stages of digging up the
relationship between sex hormones and microglia. The role of sex
hormones in neuropsychiatric disorders such as MDD, PMDD,
and postnatal depression is being gradually clarified. The exis-
tence of sex differences in a variety of physical diseases has also
been widely known, and sex hormones play crucial roles in the
pathophysiology of autoimmune diseases, such as MS, systemic
lupus erythematosus, and rheumatoid arthritis which are reported
to be more prevalent in women than in men (Duquette et al.,
1992; Ostensen et al., 2011). In contrast to this prevalence, women
with MS have better prognoses than men, and men with MS show
more progressive disease course and more severe gray matter atro-
phy (Voskuhl and Gold, 2012). Both the incidence and activity
of MS decrease during the latter half of pregnancy (Confavreux
et al., 1998), and increase in the postpartum period (Alonso et al.,
2005; Finkelsztejn et al., 2011). In addition, it has been reported
that the experience of more pregnancies increases the rate of MS
onset (Ponsonby et al., 2012). These reports imply a significant
role for sex hormones in the pathogenesis of MS. It is widely
know that microglia also play an important role in MS (Jack
et al., 2005). Regarding the pathogenesis of some psychiatric dis-
eases involved with sex differences, the interactive network where
various psychiatric diseases interact with sex hormones, the fluc-
tuation of sex hormones, and the vulnerability to the fluctuation
may be involved. Neurons have been traditionally considered to
be the main player in such interactive networks, which have been
studied with an emphasis on various neurotransmitters, for exam-
ple, glutamate (Batra et al., 2008), serotonin (Roca et al., 2002;
Hiroi et al., 2006; Dhingra et al., 2007; Landen et al., 2007; Brown
et al., 2009), and GABA (Epperson et al., 2002). We hypothesize
that not only neurons but also microglia may play an impor-
tant role as a connector in the network. Sex hormones such as
progesterone may develop and aggravate psychiatric disorders via
microglial inflammatory responses through their receptors. On
the other hand, sex hormones such as estrogen and androgen
suppress microglial inflammatory responses through their recep-
tors, which may induce therapeutic effects in psychiatric disorders
(Figure 2). In order to profoundly understand the relationship
between sex hormones, psychiatric disorders, and microglia, it is
necessary to investigate how sex hormones and microglia directly
interact, and also the microglial behavior in the above-mentioned
networks.
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FIGURE 2 | Possible link between sex hormones and microglia.
OXYTOCIN
Oxytocin is secreted by the posterior pituitary gland and syn-
thesized in the paraventricular and supraoptic of the hypothala-
mus (Moos et al., 1984). Oxytocin, which is released within the
supraoptic nucleus of hypothalamus, exerts positive feedback on
the production and release of oxytocin into the peripheral circula-
tion and the CNS (Neumann et al., 1994, 1996). Oxytocin has been
classically known as the hormone that is related to uterine con-
traction, lactation, and the regulation of atrial natriuretic peptide
(ANP) release in the cardiovascular system (Jankowski et al., 1998,
2000). Besides, oxytocin is released into the CNS and facilitates
maternal nurturing behavior, the bondage between a mother and
child, and affiliative behavior and social cognition in both sexes
(Ross and Young, 2009). Recently, the intranasal administration of
oxytocin in humans proved that oxytocin is a possible prosocial
hormone that increases trust (Kosfeld et al., 2005). In addition
to these functions, oxytocin is associated with stress-suppression
effects. In rats, the administration of a SSRI has shown to increase
the plasma concentration of oxytocin (Uvnas-Moberg et al., 1999).
In humans, the intranasal administration of oxytocin has been
reported to exert an anxiolytic effect on healthy men, and reduce
salivary concentration of cortisol in combination with social sup-
port in response to stress (Heinrichs et al., 2003). It is controversial
whether the plasma concentration of oxytocin is low in patients
with depression, but the negative correlation between plasma oxy-
tocin concentration and scores of Hamilton Depression Rating
Scale (HDRS) and the State-Trait Anxiety Inventory (STAI)/A-trait
among depressed patients has been reported (Scantamburlo et al.,
2007). A human postmortem study has revealed that the number
of oxytocin neurons increases in the PVN of the hypothalamus in
patients with MDD or bipolar disorder (Purba et al., 1996). These
reports suggest various functions of oxytocin in human mental
activities.
OXYTOCIN AND AUTISM
Recent studies have suggested that oxytocin is probably relevant to
psychiatric disorders, especially autism. The intravenous adminis-
tration of oxytocin to autistic patients increases retention of social
cognition (Hollander et al., 2007), on the other hand, the intranasal
administration of oxytocin ameliorates emotional cognition. Oxy-
tocin inhalation strengthens social interactions, induces more
adaptable social behavior, and enhances feelings of trust and pref-
erence (Andari et al., 2010). However, the underlying mechanism
explaining how oxytocin exerts these effects on autism has not been
sufficiently clarified. The relationship between autism and a vari-
ation in the CD38 gene has been reported (Munesue et al., 2010).
CD38, a multi-functional molecule, is involved in the secretion of
oxytocin. Amelioration of neural processing of social stimuli by
the intranasal administration of oxytocin depends on a CD38 gene
variant in healthy volunteers (Sauer et al., 2012). Female CD38
knockout mice defect in maternal nurturing, and male knock-
out mice impair prosocial behavior (Jin et al., 2007). Observed
in oxytocin receptor knockout mice, the intracerebroventricular
administration of oxytocin and vasopressin (AVP) ameliorates
impaired cognitive flexibility, social deficits, increased aggression,
and seizure susceptibility, which is mediated by an AVP recep-
tor (V1a) (Sala et al., 2011). These reports have suggested that
oxytocin has a variety of psychotropic, prosocial, and subsequent
therapeutic effects in animal models of autistic disorders, but in
humans with autism,whether oxytocin has therapeutic effects have
not been sufficiently validated yet so far, and needs to be further
investigated.
AUTISM AND MICROGLIA
Microglia may play an important role in autism. Rett syndrome
is classified as an ASD, mainly caused by X -linked methyl-CpG-
binding protein 2 (MeCP2) gene mutations (Amir et al., 1999).
MeCP2 gene is expressed predominantly in neurons in the CNS
and prompts neuronal differentiation (Tsujimura et al., 2009),
indicating that the etiology of Rett syndrome mainly caused
by MeCP2 gene mutations is of neuronal origin (Chen et al.,
2001). On the other hand, it has been recently suggested that
glial cells such as astrocytes and microglia are also involved with
the pathology of Rett syndrome (Maezawa et al., 2009; Maezawa
and Jin, 2010). In a mouse model of Rett syndrome, transplan-
tation of wild-type bone marrow resulted in wild-type microglial
engraftment, which showed significant improvements in autis-
tic symptoms (Derecki et al., 2012). A postmortem study on
the brains of autistic patients revealed an increase of microglia
in the fronto-insular cortex and visual cortex (Tetreault et al.,
2012). Moreover, a spatial pattern analysis of the postmortem
brains of autistic patients indicated the abnormal interaction
between microglia and neurons especially in the dorsolateral pre-
frontal cortex (Morgan et al., 2012). These postmortem studies
of child autism have suggested that the inflammatory hypothe-
ses of psychiatric disorders are, to some extent, rooted in unique
periods of vulnerability when an inflammatory assault perma-
nently re-wires the brain for the expression of these neurodevel-
opmental disorders. A recent PET study has shown that exces-
sive microglial activation in multiple brain regions has been
observed in young adult subjects with ASD (Suzuki et al., 2013).
These reports suggest that microglial activation during adulthood
may moderate the disease symptomatology of autism, while it is
unclear whether microglial activation has lasted from childhood
or not.
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CD38, OXYTOCIN, AND MICROGLIA
To the best of our knowledge, there are only a few studies
about the relationship between CD38, oxytocin, and microglia.
CD38, a multi-functional molecule involved in oxytocin secre-
tion, has some effects on microglia. Firstly, Mayo et al. (2008) have
reported that CD38 generates cyclic-adenosine diphosphate ribose
(cADPR) from nicotinamide adenine dinucleotide (NAD) as a
substrate. CD38, via cADPR as a second messenger, increases intra-
cellular calcium concentration and helps to promote microglial
activation and activation-induced cell death (AICD) in primary
mouse microglia induced by LPS/IFN-γ treatment. Secondly, Ma
et al. (2012) have reported that siRNA for CD38 gene silencing
promotes caspase 3-dependent apoptosis, which decreases sur-
vival of BV2 microglia cells. Oxytocin also interacts with microglia.
Karelina et al. (2011) have reported that oxytocin suppresses LPS-
induced expression of MHC class II dose-dependently in primary
mouse microglia.
PERSPECTIVE
Microglia and CD38 may possibly play crucial roles in the patho-
physiology and treatment of autism. Oxytocin has a variety of
effects on autistic patients (Hollander et al., 2007; Andari et al.,
2010; Sauer et al., 2012) and stress-suppression effects as men-
tioned above, which implies a yet to be fully comprehended rela-
tionship between oxytocin and microglia. However, there have
been so few reports about the relationship that we can only
be certain of the following two points; one, that unknown fac-
tors secreted by microglia inhibit the oxytocin receptor binding
in astrocytes (Mittaud et al., 2002), and two, that macrophages,
close-related with microglia, express oxytocin receptors and are
inhibited by oxytocin from secreting LPS-induced Interleukin-
6 and decreasing NADPH-dependent superoxide activity (Szeto
et al., 2008). A recently published in vitro study also showed
pro-inflammatory effects of oxytocin on activated macrophage
(Oliveira-Pelegrin et al., 2013). It is unclear and yet to be investi-
gated whether microglia could be involved with production and
release of oxytocin via direct or indirect action on the hypothala-
mus or the pituitary gland, and the interaction between oxytocin
and microglia should be clarified in the future. In addition, to our
knowledge, we are not aware whether the intranasal administra-
tion of oxytocin is physiologically comparable to hormonal levels
released by microglia or not, and this aspect should be investigated
in future research.
FINAL REMARKS; MISSING AND POSSIBLE LINKS BETWEEN
NEUROENDOCRINE FACTORS, NEUROPSYCHIATRIC
DISORDERS, AND MICROGLIA
Neuropsychiatric disorders have been mainly considered as the
consequence of abnormal conditions in neural circuitry. Many
neuropsychiatric disorders are widely known to be involved with
endocrine diseases, however the correlation has not been well
understood. Microglia have been suggested to have several impor-
tant roles in neuropsychiatric disorders. We have introduced up-
to-date knowledge on the interaction between neuroendocrine
factors, neuropsychiatric disorders, and microglia; especially high-
lighting the hormones; CRH, glucocorticoids, estradiol, and oxy-
tocin. We believe that some microglial roles may be revealed by
further research efforts in line with our proposed hypothesis.
Finally, we have shown some possible mechanisms and miss-
ing links to understand the interaction between neuroendocrine
factors, neuropsychiatric disorders, and microglia.
POSSIBLE MECHANISM
Strong psychological stress and/or physical stress induce neuroen-
docrine hormones such as CRH in the brain, which may lead
to microglial activation. Especially during childhood, microglial
over-activation due to severe stress may formulate maladaptive
neuronal networks due to a microglial impacted synaptic prun-
ing. A recent study has shown the novel role of NO as an
activity-dependent regulator of target neuron intrinsic excitability,
transforming synaptic integration and information transmission
(Steinert et al., 2011), and we suppose that microglia-derived NO
may contribute to this phenomenon. The above highlighted mal-
adaptive synaptic formulations themselves may induce psychiatric
conditions such as autistic syndrome. On the other hand, when
these maladaptations are not severe, small pathologies may be
reserved as vulnerabilities for psychiatric disorders such as schizo-
phrenia and depression in later life. Stressful life events during ado-
lescent periods and adulthood, as a secondary hit, may also activate
the above-mentioned maladaptive cascades of neuroendocrine-
microglia-neuronal networks, which may induce psychiatric con-
ditions. Based on evidence that we have introduced, we hypoth-
esize that microglia and microglia-derived mediators such as
inflammatory cytokines and free radicals may be a bridging player
between our highlighted neuroendocrine factors and psychiatric
disorders (Steiner et al., 2011; Maes et al., 2012) (Figure 3).
MISSING AND POSSIBLE LINK BETWEEN HPA AND HPG AXIS
Endocrine systems such as the HPA axis and the HPG axis commu-
nicates with the other, and these mutual interactions play impor-
tant roles in neuropsychiatric disorders (Tsigos and Chrousos,
2002; Ochedalski et al., 2007; Pittman, 2011; Schwarz and Bilbo,
2012). Many reports have indicated that the HPA axis and HPG
axis interact with each other in various ways. Concentration of
FIGURE 3 | Possible link between neuroendocrine factors,
neuropsychiatric disorders, and microglia.
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cortisol in plasma has been highly maintained during the third
trimester of normal pregnancy (Nolten et al., 1980), probably due
to high concentration of estrogen and progesterone (Bloch et al.,
2003). The concentration of CRH decreases due to the negative
feedback system during the third trimester of pregnancy, and the
low concentration of CRH remains for a period of time and causes
the hypoactivity of the HPA axis after delivery. In patients with
postpartum depression, this period of HPA axis hypoactivity is
maintained longer than in healthy puerperant women (Magiakou
et al., 1996). Cortisol level of patients with postpartum depres-
sion does not respond to the administration of ACTH, suggesting
the HPA axis dysregulation during the postpartum period (Jolley
et al., 2007). Bloch et al. have reported an abnormal response to the
alteration of sex hormones in patients with postpartum depres-
sion. They have shown the increased reactivity of cortisol to the
administration of CRH in euthymic patients with a past history of
postpartum depression (Bloch et al., 2005), and that the adminis-
tration of a high dose sex hormone followed by abrupt withdrawal
induce depressive symptoms (Bloch et al., 2000). Thus, the HPA
axis may be involved with the pathogenesis of postpartum depres-
sion. HPA axis activation has been known to suppress the HPG
axis (Petraglia et al., 1987; Polkowska and Przekop, 1997). It is
necessary to investigate the yet to be clarified microglial role in the
dynamic interactions between the HPA and HPG axis.
POSSIBLE EXAMPLE
It is epidemiologically well known that suicide has a higher preva-
lence in men, and is lower in women. This review paper has indi-
cated that progesterone/testosterone (so-called male hormones)
may induce maladaptive microglial activation, and estradiol (so-
called female hormone) may suppress microglial inflammatory
reactions. A significant number of studies suggest that testosterone
is associated with aggression, and aggression is positively linked to
suicidal behaviors (Sher, 2012). In addition, a recent postmortem
study has shown the positive link between microglial activation
and suicide (Steiner et al., 2006, 2008). Summing up such cellular,
clinical, and epidemiological evidence, we have proposed a possi-
ble mechanism – that male hormones may easily induce suicidal
acts by hormone-induced microglial activation, and estradiol may
prevent suicidal behaviors by suppressing microglial activation.
LIMITATIONS AND FUTURE PERSPECTIVE
Endocrine factors such as steroid hormones may interact with
microglia to produce inflammation-dependent neuropsychiatric
conditions. If so, what signals allow for discrimination between
schizophrenia, autism, and depression? If microglia are the com-
mon link between neuroendocrine systems and neuropsychiatric
disorders, then what differentiates the role of microglia in these
disorders? These research questions have yet to be clarified and
should be focused on in future research. As reviewed above, each
hormone affects microglia differently in different brain regions,
which might be a cue to explore the dark-side mechanism. A
growing body of evidence has revealed that abnormalities of spe-
cific brain regions contribute to each neuropsychiatric disorder
and each psychiatric condition. We suppose that the location of
the microglia-induced neuropathology may determine the specific
psychiatric abnormality. On the other hand, not only microglia but
also other brain cells such as brain macrophage, T cells, and astro-
cytes are known to release cytokines, chemokines, and free radicals.
Therefore, these alternative pathways may also be important in the
process.
Future investigations to clarify the correlation between neu-
roendocrine factors and microglia may contribute to a novel
understanding of the pathophysiology of neuropsychiatric dis-
orders and the development of effective treatment strategies.
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